Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan;27(1):36-45.
doi: 10.1007/s10875-006-9057-8. Epub 2006 Dec 29.

Rosmarinic acid induces apoptosis of activated T cells from rheumatoid arthritis patients via mitochondrial pathway

Affiliations

Rosmarinic acid induces apoptosis of activated T cells from rheumatoid arthritis patients via mitochondrial pathway

Yun-Gyoung Hur et al. J Clin Immunol. 2007 Jan.

Abstract

T cells play an important role in the initiation and the progression of rheumatoid arthritis (RA) and depletion of potentially pathogenic T cells was suggested as an important therapeutic protocol. We determined if rosmarinic acid (RosA), known as a secondary metabolite from herbal plants, had apoptotic activity toward T cells from RA patients and further verified target T-cell subsets. CD3(+)CD25(+) activated T-cell subsets from most of the RA patients displayed significantly higher apoptosis rates than did the PBMCs and total CD3(+) T cells. Furthermore, activated and effector CD4(+) T cells, including CD4(+)CD25(+) and CD4(+)CD45RO(+) T cells, had a tendency of being more susceptible to RosA-induced apoptosis than that of resting and naïve T-cell subsets. RosA induced the release of cytochrome c from mitochondria and the blockage of mitochondrial depolarization inhibited apoptosis. Taken together, these results suggest that RosA induces apoptosis of activated T-cell subsets from RA patients via a mitochondrial pathway.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Immunol. 2004 May 15;172(10):6435-43 - PubMed
    1. Nat Rev Immunol. 2003 Dec;3(12):939-51 - PubMed
    1. Ther Apher. 1999 May;3(2):178-85 - PubMed
    1. J Immunol. 2004 Jan 1;172(1):79-87 - PubMed
    1. Lab Invest. 2003 Dec;83(12):1839-48 - PubMed

Publication types

MeSH terms